Wyeth-Ayerst Low-Dose Premarin Filings Slated For 2000
Wyeth-Ayerst is planning to file for FDA approval of lower dose formulations of its conjugated estrogen product Premarin by the end of the year.
You may also be interested in...
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011